Suppr超能文献

313 例西方患者的肝细胞癌肝切除术:肿瘤生物学和潜在肝脏而非肿瘤大小决定预后。

Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis.

机构信息

Service de Chirurgie Digestive et Hépatobiliaire, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris-Université Paris-Est, Créteil, France; Section of Gastrointestinal Surgery, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, United States.

Service de Chirurgie Digestive et Hépatobiliaire, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris-Université Paris-Est, Créteil, France.

出版信息

J Hepatol. 2015 May;62(5):1131-40. doi: 10.1016/j.jhep.2014.12.018. Epub 2014 Dec 18.

Abstract

BACKGROUND & AIMS: Treatment decisions for hepatocellular carcinoma are mostly guided by tumor size. The aim of this study was to analyze resection outcomes according to tumor size and characterize prognostic factors.

METHODS

Patients resected at a Western center between 1989 and 2010 were grouped by largest tumor size: <50mm, 50-100mm, and >100mm. The primary end points were overall- and recurrence-free survival. Univariate associations with primary endpoints were entered into a Cox proportional hazard regression model.

RESULTS

Three hundred thirteen patients underwent resection: 111 (36%) had tumors <50mm, 113 (36%) had tumors between 50 and 100mm, and 89 (28%) had tumors >100mm. Five-year overall and disease-free survival rates for the three groups were 67%, 46%, and 34%, and 32%, 27%, and 27%, respectively. Thirty-five patients, mostly from <50mm group, underwent transplantation which was associated with a 91% 5 year survival rate. Tumor size was not an independent predictor of overall or recurrence-free survival on multivariate analyses. Independent predictors of decreased overall survival were: intraoperative transfusion (HR=2.60), cirrhosis (HR=2.42), poorly differentiated tumor (HR=2.04), satellite lesions (HR=1.69), alpha-fetoprotein >200 (HR=1.53), and microvascular invasion (HR=1.48). The use of salvage transplantation was an independent predictor of improved survival (HR=0.21). Recurrence-free survival was predicted by intraoperative transfusion (HR=2.15), poorly differentiated tumor (HR=1.87), microvascular invasion (HR=1.71) and cirrhosis (HR=1.69).

CONCLUSION

By studying a large group of patients across a distribution of tumor sizes and background liver diseases, it is demonstrated that size alone is a limited prognostic factor. Tumor biology and condition of the underlying liver are better prognosticators and should be given closer attention. Although hampered by recurrence rates, resection is safe and offers good overall survival. In addition, it may allow for better selection for salvage transplantation after consideration of histopathological risk factors.

摘要

背景与目的

肝细胞癌的治疗决策主要取决于肿瘤大小。本研究旨在根据肿瘤大小分析切除术的结果,并确定预后因素。

方法

在 1989 年至 2010 年间,在一家西方中心接受手术的患者按最大肿瘤大小分组:<50mm、50-100mm 和>100mm。主要终点是总生存期和无复发生存期。将与主要终点相关的单变量因素纳入 Cox 比例风险回归模型。

结果

共有 313 例患者接受了切除术:111 例(36%)肿瘤<50mm,113 例(36%)肿瘤在 50-100mm 之间,89 例(28%)肿瘤>100mm。三组患者的 5 年总生存率和无病生存率分别为 67%、46%和 34%,32%、27%和 27%。35 例患者主要来自<50mm 组,接受了移植手术,5 年生存率为 91%。多变量分析显示,肿瘤大小不是总生存期和无复发生存期的独立预测因素。总生存期降低的独立预测因素包括术中输血(HR=2.60)、肝硬化(HR=2.42)、低分化肿瘤(HR=2.04)、卫星病变(HR=1.69)、甲胎蛋白>200ng/ml(HR=1.53)和微血管侵犯(HR=1.48)。挽救性移植的应用是改善生存的独立预测因素(HR=0.21)。无复发生存期的预测因素包括术中输血(HR=2.15)、低分化肿瘤(HR=1.87)、微血管侵犯(HR=1.71)和肝硬化(HR=1.69)。

结论

通过对一组大小分布和背景肝脏疾病的患者进行研究,证明大小本身是一个有限的预后因素。肿瘤生物学和基础肝脏状况是更好的预后指标,应给予更密切的关注。尽管复发率较高,但切除术是安全的,总体生存率较高。此外,在考虑组织病理学危险因素后,它可能允许更好地选择挽救性移植。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验